Eli Lilly Bamlanivimab Playbook; Regeneron Emergency Use Authorization (EUA) Guidebook, and Other Related Resources.

Welcome! NICA has collaborated with Eli Lilly and Regeneron to develop in-depth guidance about the COVID-19 antibody therapies currently available under Emergency Use Authorization. Links to additional resources on external sites can also be found here.

Regeneron Guidebook Tile
Regeneron Casirivimab + Imdevimab Emergency Use Authorization (EUA) Guidebook

NICA collaborated with Regeneron to develop this playbook with in-depth information about Casirivimab + Imdevimab.

Lilly Playbook Tile
Eli Lilly Bamlanivimab Playbook

Eli Lilly and NICA collaborated to develop a playbook with in-depth information about the Emergency Use Authorization, regulatory requirements, allocation, ordering, infusion site of care requirements, resources and considerations.

Nica resources tile 1
Nica resources tile 2
Bam for Healthcare Providers Tile
Bamlanivimab for Healthcare Providers

Click on the heading or graphic to be redirected to the bamlanivimab website for healthcare providers.

Bam Fact Sheet English Tile
Bamlanivimab Fact Sheet for Patients, Parents, and Caregivers (English)

This is the fact sheet (in English) for patients, parents, and caregivers for the Emergency Use Authorization (EUA) of Bamlanivimab.

Bam Fact Sheet Spanish Tile
Bamlanivimab Fact Sheet for Patients, Parents, and Caregivers (Spanish)

This is the fact sheet (in Spanish) for patients, parents, and caregivers for the Emergency Use Authorization (EUA) of Bamlanivimab.

Bam Fact Sheet for Healthcare Providers
Bamlanivimab Fact Sheet for Healthcare Providers

Fact Sheet for Healthcare Providers: Emergency Use Authorization (EUA) of Bamlanivimab

for hcp
Casirivimab + Imdevimab for Healthcare Providers

Click on the heading or graphic to be redirected to the Casirivimab + Imdevimab website for healthcare providers.

english
Casirivimab + Imdevimab Fact Sheet for Patients, Parents, and Caregivers (English)

Fact Sheet in English for Patients, Parents, and Caregivers: Emergency Use Authorization (EUA) of Casirivimab + Imdevimab

spanish
Casirivimab + Imdevimab Fact Sheet for Patients, Parents, and Caregivers (Spanish)

Fact Sheet in Spanish for Patients, Parents, and Caregivers: Emergency Use Authorization (EUA) of Casirivimab + Imdevimab

Fact Sheet for HCP
Casirivimab + Imdevimab Fact Sheet for Healthcare Providers

Fact Sheet in English for Patients, Parents, and Caregivers: Emergency Use Authorization (EUA) of Casirivimab + Imdevimab

dear hcp letter
Casirivimab + Imdevimab "Dear Healthcare Provider," Letter

A letter to healthcare providers to call attention to packaging and correct dosing to prevent medication errors.

Multilingual COVID resources
Multilingual COVID-19 Resources

The CDC has developed the COVID-19 Communication Toolkit: For Migrants, Refugees, and Other Limited-English-Proficient Populations in various languages. Resources are available in Spanish, Simplified Chinese, Korean, Tagalog, Hmoob (Hmong), Af Soomaali (Somali), and Vietnamese.

Operation Warp Speed Tile
Operation Warp Speed

Learn more about the ongoing effects to develop and distribute COVID-19 therapeutics.

CDC Tile
Centers for Disease Control and Prevention

The Centers for Disease Control and Prevention’s Coronavirus (COVID-19) Website

MedWatch Tile
Report an Adverse Event to MedWatch

Healthcare providers must submit a report on all medication errors and all serious adverse events potentially related to COVID-19 antibody therapy.